Genelux Corp. (GNLX)
NASDAQ:GNLX
Want to see GNLX full AI Analyst Report?
GNLX Stock Chart & Stats
$2.79
-$0.06(-2.24%)
At close: 4:00 PM EST
$2.79
-$0.06(-2.24%)
Day’s Range― - ―
52-Week Range$2.26 - $8.54
Previous CloseN/A
Volume23.79K
Average Volume (3M)156.94K
Market Cap
$122.77M
Enterprise Value$90.39M
Total Cash (Recent Filing)$14.60M
Total Debt (Recent Filing)$1.69M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
May 13, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding44,805,813
10 Day Avg. Volume178,540
30 Day Avg. Volume156,945
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)14.04
Price to Sales (P/S)20261.21
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue11.30K
Enterprise Value/Gross Profit-319.41
Enterprise Value/Ebitda-2.77
Forecast
1Y Price Target
$21.00Price Target Upside652.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial RunwayRecent equity financing and available cash are expected to provide runway to reach pivotal clinical milestones, reducing near-term funding uncertainty for ongoing development programs.
Mechanism Of ActionOlvi-Vec's triple anti-cancer mode—direct tumor cell lysis, tumor-specific immune activation, and durable anti-cancer memory—plus its ability to upregulate STAT1 and break down tumor stroma offers a differentiated therapeutic approach that can resensitize tumors to platinum chemotherapy.
Sector TailwindsRenewed regulatory interest and growing investor attention in oncolytic virus therapies create market tailwinds that could increase visibility and valuation for the company's programs.
Bears Say
Dose-finding RiskLimited dosing information from early cohorts means additional dose-finding is required to identify an optimal therapeutic dose and to support expansion into broader indications.
Small Patient CohortsVery small patient numbers in early lung studies limit confidence in observed responses and leave uncertainty about whether initial results will be confirmed in larger populations.
Statistical UncertaintyInterim findings based on very small groups reduce statistical confidence and increase the risk that early efficacy signals will not replicate in pivotal trials.
Genelux Corp. News
GNLX FAQ
What was Genelux Corp.’s price range in the past 12 months?
Genelux Corp. lowest stock price was $2.25 and its highest was $8.54 in the past 12 months.
What is Genelux Corp.’s market cap?
Genelux Corp.’s market cap is $122.77M.
When is Genelux Corp.’s upcoming earnings report date?
Genelux Corp.’s upcoming earnings report date is May 13, 2026 which is in 9 days.
How were Genelux Corp.’s earnings last quarter?
Genelux Corp. released its earnings results on Mar 19, 2026. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.218 by -$0.022.
Is Genelux Corp. overvalued?
According to Wall Street analysts Genelux Corp.’s price is currently Undervalued.
Does Genelux Corp. pay dividends?
Genelux Corp. does not currently pay dividends.
What is Genelux Corp.’s EPS estimate?
Genelux Corp.’s EPS estimate is -0.2.
How many shares outstanding does Genelux Corp. have?
Genelux Corp. has 44,805,813 shares outstanding.
What happened to Genelux Corp.’s price movement after its last earnings report?
Genelux Corp. reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.218. Following the earnings report the stock price went down -5.512%.
Which hedge fund is a major shareholder of Genelux Corp.?
Currently, no hedge funds are holding shares in GNLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genelux Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (652.69% Upside)
$21.00 (652.69% Upside)
Hedge Fund Trend
Decreased
By 631.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.72%
12-Months-Change
Fundamentals
Return on Equity
-153.29%
Trailing 12-Months
Asset Growth
-45.19%
Trailing 12-Months
Company Description
Genelux Corp.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
GNLX Stock 12 Month Forecast
Average Price Target
$21.00
▲(652.69% Upside)
Technical Analysis
Coherus Biosciences
―
Fate Therapeutics
―
Tonix Pharma
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Ownership Overview
3.68% Insiders
3.86% Mutual Funds
5.71% Other Institutional Investors
82.81% Public Companies and
Individual Investors